Phentermine vs Ozempic: A Stimulant Pill vs a GLP-1 for Weight Loss

Ozempic vs phentermine is less a contest than a mismatch of purpose. Phentermine is a stimulant approved as a short-term add-on to a weight-loss plan.

Semaglutide, the drug in Ozempic, is a GLP-1 receptor agonist whose weight-management version, Wegovy, is approved for long-term use. In trials, semaglutide comes out well ahead: 14.9% average weight loss at 68 weeks on Wegovy 2.4 mg, against 7.4% at 28 weeks on phentermine 15 mg in a separate trial. Price, a pill instead of a shot and a track record back to 1959 favor phentermine.

One naming point matters. Ozempic is FDA-approved for type 2 diabetes, not for weight loss. Wegovy is the approved semaglutide product for weight loss.

Phentermine vs semaglutide is also a comparison of two eras of obesity medicine. Phentermine for weight loss dates to 1959, before regulators required long-term trials, while semaglutide arrived with trials that followed thousands of people for more than a year. Searches for phentermine vs GLP 1 drugs come down to four questions.

How each drug curbs appetite

Chemically, phentermine is related to amphetamine and acts on the central nervous system. MedlinePlus calls it an appetite suppressant, though its FDA label notes that appetite suppression has not been proven to be its main action and other nervous system or metabolic effects may contribute. Tolerance to the appetite effect usually builds within a few weeks.

Semaglutide copies GLP-1, a hormone your gut releases after a meal, acting on brain areas that regulate appetite and calorie intake and slowing how fast your stomach empties. Our guide to how semaglutide works for weight loss explains the mechanism.

Weight loss results

No trial has compared the two directly, so these are separate placebo-controlled studies. In a 28-week trial summarized in the ADA's 2026 Standards of Care, adults lost 7.4% of body weight on phentermine 15 mg and 6.6% on 7.5 mg, against 2.3% on placebo (ADA Standards of Care, Section 8). A 2025 trial in people who had not responded to diet counseling found 5.9% on 15 mg against 2.8% over 24 weeks.

In STEP 1, adults without diabetes on Wegovy 2.4 mg lost 14.9% of body weight over 68 weeks, against 2.4% on placebo (Wegovy prescribing information). Even the phentermine label is candid: its extra loss over placebo in short trials was a fraction of a pound a week.

How long you can take each

This is the sharpest difference. On its label, phentermine is a short-term adjunct, and MedlinePlus says most people take it for 3 to 6 weeks. Wegovy is approved to reduce weight and keep it off. The ADA recommends staying on long-term obesity medicines after you reach a goal, because stopping often brings the weight back.

Some prescribers use phentermine longer, off label. A large 2019 health-records study found people who stayed on it for more than a year lost more weight, with no clear rise in heart events, but it was observational. The first long-term randomized trial is still running (ClinicalTrials.gov).

Price & access

Generic phentermine costs little: the ADA's 2026 tables put pharmacy acquisition cost for a month of the 37.5 mg dose at about $2, though the counter price depends on your pharmacy. As a Schedule IV controlled substance under federal law, it is more tightly regulated than most prescriptions (DEA).

Brand semaglutide costs far more. The same ADA tables list Wegovy at $1,619 wholesale for 30 days, and a federal program announced in February 2026 lists Ozempic and injectable Wegovy at an average of $350 a month, depending on dose. Harbor's compounded semaglutide starts at $99 a month, prepared by a licensed U.S. pharmacy, and is not FDA-approved.

Scroll the table sideways to see both columns →

Semaglutide vs phentermine is a decision for a licensed clinician who knows your heart health, blood pressure and history. Each label sets out who should not take the drug, and those lists rule many people out before results enter the picture.

Phentermine may be considered when:

• You need a short, low-cost start alongside diet and exercise changes
• Your BMI is 30 or more, or 27 or more with a condition such as controlled high blood pressure or diabetes
• You have no heart disease, uncontrolled blood pressure, hyperthyroidism, glaucoma or history of drug misuse, and you are not pregnant

Semaglutide may be considered when:

• You want a medication approved for long-term weight management
• You have type 2 diabetes, where the ADA prefers semaglutide or tirzepatide for people with overweight or obesity
• A stimulant is not a safe option because of your heart, blood pressure or a history of agitation

Side effects differ in kind. For phentermine, the label lists dry mouth, insomnia, restlessness, palpitations and raised blood pressure, and you should not take it late in the day. On Wegovy 2.4 mg, nausea affected 44% of adults against 16% on placebo, diarrhea 30% and vomiting 24%, mostly while the dose was rising, and resting heart rate rose 1 to 4 beats per minute on average.

Harbor's weight-loss programs use compounded semaglutide injections and compounded tirzepatide. A board-certified physician reviews your intake, and if it is not the right fit, it is not prescribed.

In the GLP 1 vs phentermine question, semaglutide has the larger effect, the long-term approval and no stimulant risks. Phentermine has the low price and the pill. The ADA's 2026 guidance groups phentermine with the older short-term drugs and names semaglutide and tirzepatide as preferred for people with diabetes and obesity.

For how this class of medicine works, see the science of GLP-1s.